Merck’s New Spinoff Organon Shows How Women’s Health Can Provide Fertile Ground For Investment. Here’s Why.
Jun 15, 2021
It may be 2021, but the issue of women’s health – especially reproductive rights, birth control and fertility issues – is one which still provokes heated debate and makes headlines around the world. Considering the global women’s health market is predicted to be worth $50 billion by 2025, it seems somewhat ironic that one of the more silent voices tends to be that of Big Pharma.
Heavy hitters are getting out of the game and moving away from investment in the sector, with multi-national pharmaceutical company Merck & Co., Inc. (MRK) Spinning off Organon & Co. (OGN) earlier this month. However, according to analysis from The Edge, it looks like OGN may be the big winner here.
Founded in the Netherlands in 1923, OGN became a world-leading pioneer in contraceptives, and while it’s going back to its roots post-Spin, it has clearly renewed its focus on medical breakthroughs and future-proofing its brand. Stepping into a space which is largely ignored and focusing on ground-breaking contraceptives could be the secret weapon in its armory.